Loss of β-2M can lead to loss of MHC class 1 and compatible presentation of tumor antigens, which in turn hinders effective anti-tumor reactions and contributes to immune evasion and therapy resistance [245,246]. The gene discussed is B2M; the disease is neoplasm.